Rilpivirine , ≥98% , 500287-72-9
| Pack Size | Price | Stock | Quantity |
| 10MG | RMB55.20 | In Stock |
|
| 50MG | RMB183.20 | In Stock |
|
| 100mg | RMB346.40 | In Stock |
|
| 250mg | RMB663.20 | In Stock |
|
| 1g | RMB1656.80 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 245℃ |
| Boiling point: | 634.1±65.0 °C(Predicted) |
| Density | 1.27 |
| storage temp. | Refrigerator |
| solubility | Acetone (Slightly), Chloroform (Slightly), DMSO (Slightly), Water (Very Slightly) |
| pka | 4.56±0.10(Predicted) |
| form | Solid |
| color | Yellow |
Description and Uses
In May 2011, the U.S. FDA approved rilpivirine in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) 1 infection in treatment-naive adult patients. Rilpivirine is a member of the nonnucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV agents. It is highly potent against a range of wild-type HIV strains (EC50=0.07–1.0 nM),～10–20 timesmore potent than the NNRTI efavirenz (Sustiva), and active against HIV strains resistant to other NNRTIs. The discovery of rilpivirine was guided by molecular modeling and X-ray crystallography of HIV-1 RT complexed with inhibitors. The synthesis of rilpivirine is accomplished by an efficient 6-step route in which the key step is coupling of 4-((4-chloropyrimidin-2-yl)amino)benzonitrile with (E)-3-(4-amino-3,5-dimethylphenyl)acrylonitrile.
A novel non-nucleoside reverse transcriptase inhibitor. Rilpivirine seems to be well tolerated with less CNS disturbance than Efavirenz, and has non-teratogenic potential. An anti-HIV agent.
Safety
| Symbol(GHS) |   GHS07,GHS09 |
| Signal word | Warning |
| Hazard statements | H319-H400-H302-H410 |
| Precautionary statements | P273-P391-P501-P264-P270-P301+P312-P330-P501-P273-P391-P501-P264-P280-P305+P351+P338-P337+P313P |
| Hazardous Substances Data | 500287-72-9(Hazardous Substances Data) |
